Nereus Raises $20M for Cancer Study

Xconomy San Diego — 

San Diego’s Nereus Pharmaceuticals says it has secured as much as $20 million in commitments for additional funding from its existing investors to fund a mid-stage trial of a drug candidate for treating non-small cell lung cancer. The company, which specializes in developing drugs from marine microbes, says it has enrolled 170 patients in its study of NPI-2358 (plinabulin). As Luke reported last year, Nereus previously raised $125 million. Investors are HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund, and Astellas Venture Management.